Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration

Venous Ulcer Clinical Trial

— DAVE  

Official title:

Decellularised Dermis Allograft for the Treatment of Chronic Venous Leg Ulceration

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04021316
• Other study ID #: 19CX5371
• Status: Terminated
• Phase: N/A
• Start date: October 1, 2019
• Est. completion date: April 10, 2023

Study information

• Verified date: September 2023
• Source: Imperial College London
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Does the use of decellularised dermis allograft in addition to compression therapy promote healing in chronic venous leg ulceration compared to compression therapy alone

Description:

Chronic venous ulceration are open wounds on the lower limbs which have been present for at least three months and are caused by a poorly functioning venous system. The affect about 1% of the general population and about 4% of those over 65. The wounds cause pain, reduced movement, and can smell - greatly affecting the quality of life of leg ulcer patients. The standard care for these patients is compression bandaging, which requires changing several times a week by community or district nurses; this drives the high cost of leg ulcer care, which can amount to £2.5 billion per annum. Skin grafting can be used alongside compression bandaging and can help the ulcers heal faster than compression alone. Grafts can be taken from the patient's own skin, from a donor or from tissue engineered skin. An autograft (using own skin) can cause scarring and the need for a formal surgical procedure in theatre so are not suitable for all ulcer patients. Allografts (donor skin) and xenografts (animal skin) have been used successfully, but present similar drawbacks to autografts, plus the potential for the body to reject the graft and disease transmission. Tissue engineered skin has several advantages as it has been processed to remove the cells, and therefore is won't be rejected via the immune response. Human decellularised dermis (DCD) is generated from donated skin from deceased people and processed to remove the cells. It can be glued or sewn onto the skin under local anesthetic, in an out patient setting. DCD has mainly been studied in patients with diabetic foot ulceration and has shown improved healing rates and quality of life. This study will investigate the use of DCD in addition to compression therapy versus compression therapy alone in patients with chronic venous leg ulceration.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 71
• Est. completion date: April 10, 2023
• Est. primary completion date: April 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• =18 years or older (no upper age limit)
• The ability to consent to participation
• A diagnosis of venous leg ulceration* (defined as 'colour duplex confirmation of superficial and or deep venous reflux with any break in the skin that has either: a) been present for more than 2 weeks, or b) occurred in a person with a history of venous leg ulceration)
• Documented venous incompetence on duplex ultrasound
• Index ulcer wound duration of greater than 3 months
• Index ulcer wound size = 2 cm2.
• ABPI = 0.8
• in light of the Covd-19 pandemic, the use of handheld continuous wave Dopplers will be allowed to diagnose venous disease to allow participants to be recruited from clinic without the need for an imaging appointment

Exclusion Criteria:

• A diagnosis of sickle cell
• Unable to receive one or more of the randomised treatment strategies for any reason at the discretion of the attending clinical team (e.g. known allergies to dCELL dermis preparation components)
• A clinically infected ulcer defined as evidence of erythema, cellulitis or systemically unwell
• Treatment with biomedical/topical growth factors within previous 30 days
• Previous history of an inability to tolerate compression therapy
• Foot ulcer (i.e. below the ankle)

Related Conditions & MeSH terms

• Allograft
• Varicose Ulcer
• Venous Ulcer

Intervention

Other:
• dCELL® Human Dermis (decellularised dermal skin allograft - DCD)
DCD is produced from split thickness skin grafts (which comprise the epidermis and upper part of the dermis), and is retrieved from deceased tissue donors. All epidermal and cellular components from the dermis are removed in a patented sequential decellularisation process. As a decellularised graft, dCELL® Human Dermis fully integrates into the wound bed after application, replacing lost dermal tissue. It provides a scaffold into which the recipient's cells can grow, becoming vascularised and supporting the generation of a new epidermis, ultimately regenerating into normal skin.
• Compression bandaging therapy
Compression therapy will be according to local practice and may include multilayer elastic compression bandaging or stockings delivering 20 to 40mm/Hg pressure.

Locations

Country	Name	City	State
United Kingdom	North Bristol NHS Trust	Bristol
United Kingdom	Cardiff and Vale University Health Board	Cardiff
United Kingdom	North Cumbria University Hospitals NHS Trust	Carlisle
United Kingdom	Gloucestershire Hospitals NHS Foundation Trust	Gloucester
United Kingdom	AT Medics	London
United Kingdom	Guy's and St Thomas' NHS Foundation Trust	London
United Kingdom	Imperial College Healthcare NHS Trust	London
United Kingdom	London North West University Healthcare	London
United Kingdom	St Charles Centre for Health and Welbeing, Central London Community Healthcare NHS Trust	London
United Kingdom	Aneurin Bevan University Health Board	Newport
United Kingdom	Northampton General Hospital NHS Trust	Northampton
United Kingdom	Livewell	Plymouth
United Kingdom	University Hospitals Plymouth NHS Trust	Plymouth
United Kingdom	Swansea Bay University Health Board	Swansea
United Kingdom	Taunton and Somerset NHS Foundation Trust	Taunton
United Kingdom	Mid Yorkshire Hospitals NHS Trust	Wakefield
United Kingdom	Worcestershire Acute Hospitals NHS Trust	Worcester

Sponsors (8)

Lead Sponsor	Collaborator
Imperial College London	Cambridge University Hospitals NHS Foundation Trust, Gloucestershire Hospitals NHS Foundation Trust, NHS Blood and Transplant, Universidad de Granada, University of Birmingham, University of Edinburgh, University of Manchester

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion with a healed index ulcer at 12 weeks after randomisation.		12 weeks
Secondary	Time to index ulcer healing from randomisation		12 months
Secondary	The percentage change in index ulcer area in cm2 at 12 weeks from randomisation		12 weeks
Secondary	The proportion of participants with a healed index ulcer at 12 months from randomisation		12 months
Secondary	The proportion of participants whose index ulcer healed for whom an ulcer recurred at the index site within 12 months from randomisation		12 months
Secondary	Generic quality of life using the EuroQol-5D (EQ-5D) questionnaire	A health index on a score of 0 to 1 and the participants' self-rated health on a vertical score of zero to 100. Higher scores indicate better quality of life	12 weeks, 6 months and 12 months from randomisation
Secondary	Disease specific quality of life using the Charing Cross Venous Ulcer Questionnaire (CCVUQ)	Scale 0 to 100, with lower scores indicating better quality of life	12 weeks, 6 months and 12 months from randomisation
Secondary	The cost for each patient, calculated from the healthcare resources used		12 months
Secondary	Incremental cost-effectiveness ratio (ICER) from the EQ-5D questionnaire, with appropriate sensitivity analysis	An intervention may be considered cost-effective when its ICER is less than the threshold set by health policy decision-makers. In the UK, the cost-effectiveness threshold is currently in the range £20 000-30 000 per QALY	12 months